OnKure is committed to the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancer. As a team of veterans with a track record of successful drug discovery and development, we are leveraging our proven structure-based drug design approach to create a robust pipeline of drug candidates that are designed to achieve optimal tolerability and efficacy. OnKure is currently developing bocodepsin (OKI-179), an oral Class I HDAC inhibitor, for the treatment of both hematological and solid tumors, in addition to OKI-219, a selective PI3K alpha H1047R inhibitor. In the evolving landscape of precision oncology, our successful tumor-agnostic approach is key to discovering new treatments for cancer patients with unmet medical needs.